9 results about "Natriuretic peptide" patented technology

The present application relates to a kind of kit and detection method for detecting heart failure marker, belong to heart failure marker detection technical field.The kit includes basic buffer A (pH=7.4, containing 0.5mol / L NaCl and 10mmol / L Tris aqueous solution), basic buffer B (pH=7.4, containing 3mol / L NaCl and 10mmol / L Tris aqueous solution) and washing liquid (0.5~3mol / L alkali metal chloride).The detection method disclosed in the present application mainly forms ion gradient direction on the two sides of the electrochemical device with nano-pore respectively by basic buffer A and basic buffer B, releases the electrochemical signal characteristics of large sodium peptide, compares the sample characteristic map of serum sample with the sample characteristic map of standard B-type natriuretic peptide by the amplitude of current signal and current block time characteristic analysis, detects and quantifies B-type natriuretic peptide in serum to-be-detected object, and its detection limit is as low as 767.92fmol / L.

The present disclosure, relates, in general, to stable variants of C-type natriuretic peptide (CNR) and uses thereof to treat bone-related disorders.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

A method, system, and medium for dynamically controlling infusion drip rate based on patient physiological parameters include: acquiring real-time physiological parameter data, medical history data, and drug attribute data of the patient; real-time physiological parameter data including glomerular filtration rate and B-type natriuretic peptide concentration; obtaining a safe drip rate range based on one or more of the real-time physiological parameter data, medical history data, and drug attribute data according to a preset rule base; calculating a recommended drip rate based on a machine learning model and a standard drip rate; obtaining a preset drip rate threshold range, and generating and outputting a first drip rate control command based on the recommended drip rate, the safe drip rate range, and the preset drip rate threshold range; monitoring the actual drip rate in real time and calculating the error value between the actual drip rate and the recommended drip rate; and dynamically adjusting the first drip rate control command based on the error value using a closed-loop control algorithm to generate and output a second drip rate control command.

The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.

The present invention relates to natriuretic peptide analogues with enhanced stability and a pharmaceutical composition comprising same. Exhibiting a prolonged in vivo half-life, high bioavailability, and a high bone growth rate as well as being relatively short sequence length, a C-type natriuretic peptide analogue according to an embodiment of the present invention has advantages of being easy to synthesize and reducing production costs, and thus is expected to be effectively used in compositions for promoting growth and in the prevention or treatment of bone-related diseases.

This invention discloses a mutant G-type natriuretic peptide (GNP) and its applications. The mutant GNP contains an amino acid substitution at position 14 of the mature GNP peptide or its truncated form as shown in SEQ ID NO:1, wherein the amino acid substitution is P14R. This invention also discloses immunoconjugates, nucleic acids, recombinant vectors, host cells, pharmaceutical compositions, and uses containing this mutant GNP. Compared to the mature GNP peptide, this mutant GNP exhibits enhanced natriuretic peptide receptor A activity and / or natriuretic peptide receptor B activity, and better vasodilatory induction.

Provided are chimeric molecules, compositions, and applications thereof that specifically bind to natriuretic peptide receptor C (NPR-C). The disclosed chimera comprises an NPR-C binding domain and a target-binding domain. Through NPR-C-mediated endocytosis, the chimera enables the intracellular degradation of the target by lysosomal enzymes. The chimeric molecules can rapidly, conveniently, and precisely degrade target proteins. Their modular design permits broad applicability to proteins such as secreted proteins and membrane-associated proteins. These chimeric molecules exhibit high bioavailability and low immunogenicity, thus being broadly applicable for the treatment of diseases including cancer, neurodegenerative diseases, psychiatric disease, central nervous system diseases, inflammatory diseases, autoimmune diseases, metabolic syndrome, tissue fibrotic disease, cardiovascular diseases, respiratory diseases, digestive diseases, renal diseases, hematologic diseases, infectious diseases, rare diseases and aging-related disease.